Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AARD vs GAINL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GAINL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–0 Matrix Metrics)

GAINL Overall Winner 6-Pillar Tally: AARD 2 – 4 GAINL Matrix Metrics: AARD 0 – 8 GAINL

As of Nov 20, 2026, Gladstone Investment Corporation 8.00% Notes due 2028 (GAINL) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AARD carries a Unified Composite Score of 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin), whereas GAINL carries 59.2/100 (HOLD) at $25.21 (N/M Forward P/E, 42.5% operating margin).

  • Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile GAINL is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AARD vs GAINL
AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.74% 1D
Market Cap $21.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.84β · 284% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.6%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.25 · SMA50: $3.35
GAINL NASDAQ Head-to-Head Winner
Gladstone Investment Corporation 8.00% Notes due 2028
Institutional Equity
$25.21
+0.13% 1D
Market Cap $358.3M
TTM Revenue $64M
Forward P/E N/M
Beta / 30D Vol 0.02β · 2% Vol
Unified Composite Score
59.2 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 50.0 Mom 48.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.7%) with fading momentum, RSI 44
RSI-14: 44.0 · SMA20: $25.19 · SMA50: $25.49

6-Pillar Scorecard Institutional Category Breakdown (AARD 2 – 4 GAINL)

Columns: Metric · AARD · GAINL
1. Valuation Multiples GAINL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 5.6x
2. Growth & Scale GAINL
Revenue Growth (YoY) +0.0% +68.4%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A $64M
Market Cap $21.9M $358.3M
3. Profitability & Quality GAINL
Gross Margin N/A 88.6%
Operating Margin 0.0% 42.5%
Net Profit Margin 0.0% 140.1%
Return on Equity (ROE) -66.0% 22.9%
4. Balance Sheet & Cash Flow AARD
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $73M Net Cash $12.66 Book/Sh · 22.9% ROE
Dividend Yield None (0.00%) 7.78%
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 147.3% (26th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat GAINL
OpEx & R&D Intensity N/A 46.1% of Rev ($29M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Specialty Finance Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AARD (0) vs GAINL (8)
Institutional Metric AARD GAINL Criterion Row Edge
Market Capitalization
Scale
$21.9M $358.3M Larger Scale GAINL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +68.4% Higher Growth GAINL
Operating Margin (TTM)
Profitability
0.0% 42.5% Higher Margin GAINL
Net Profit Margin
Profitability
0.0% 140.1% Higher Margin GAINL
Return on Equity (ROE)
Capital Efficiency
-66.0% 22.9% Higher ROE GAINL
52-Week Range Position
Momentum
0% ($1–$17) 9% ($25–$26) Stronger Trend GAINL
Beta / 30D Volatility
Risk Regime
3.84β · 284% Vol 0.02β · 2% Vol Lower Realized Risk GAINL
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 59.2 / 100 (HOLD) Higher Composite GAINL
Trailing 12M Revenue (USD)
Operating Scale
N/A $64M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($73M Net Cash) N/A ($12.66 Book/Sh · 22.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AARD +38.1 pp
AARD: +38.34% · GAINL: +0.24%
3M Horizon AARD +38.1 pp
AARD: +38.34% · GAINL: +0.24%
6M Horizon AARD +38.1 pp
AARD: +38.34% · GAINL: +0.24%
1Y Horizon AARD +38.1 pp
AARD: +38.34% · GAINL: +0.24%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AARD vs GAINL. Trailing 12-month operating profitability (AARD 0.0% vs GAINL 42.5%) and valuation multiples (AARD N/M vs GAINL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M
GAINL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$64M
Gross Margin88.6%
Op. Margin42.5%
ROE / Fwd P/E22.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GAINL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GAINL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $21.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GAINL Moat Profile High-Margin Pricing Power Moat
Specialty Finance Operator
Competes within the Specialty Finance value chain with $358.3M market capitalization and 42.5% operating margin.
OpEx & R&D Reinvestment 46.1% of Rev ($29M)
90D Engineering Disclosures 0 Published

Investor FAQ AARD vs GAINL Key Questions & Quantitative Answers

As of Nov 20, 2026, Gladstone Investment Corporation 8.00% Notes due 2028 (GAINL) is the stronger overall head-to-head candidate over Aardvark Therapeutics, Inc. (AARD) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AARD carries a Unified Composite Score of 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin), whereas GAINL carries 59.2/100 (HOLD) at $25.21 (N/M Forward P/E, 42.5% operating margin). Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile GAINL is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GAINL leads the Growth & Scale pillar: AARD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GAINL at +68.4% YoY revenue growth and N/A YoY earnings growth on $64M TTM revenue (88.6% gross margin, 42.5% operating margin). On trailing 12-month operating scale, AARD generates N/A in USD-normalized revenue versus $64M for GAINL. In operating R&D and SG&A reinvestment, AARD deploys N/A (0 90-day corporate R&D disclosures) versus 46.1% of Rev ($29M) (0 disclosures) for GAINL.

GAINL screens cheaper on headline valuation multiples. AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GAINL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.6x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AARD (-66.0% ROE) versus GAINL (22.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.84β · 284% Vol realized risk). By comparison, GAINL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.